
em e	· · · · · · · · · · · · · · · · · · ·	Book DOTIDTO - 4 COT							
P.26087; P01		Rec'd PCT/PTO 21 OCT							
Form PTO-1390	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE								
TRANSMITTAL LETTER TO DESIGNATED/ELECTED CONCERNING A FILING	OFFICE (DO/EO/US)								
INTERNATIONAL APPLICATION NO. PCT/JP03/05084	INTERNATIONAL FILING DATE 22 April 2003	PRIORITY DATE CLAIMED 22 April 2002							
TITLE OF INVENTION: MEDICAMENT I	FOR THERAPEUTIC TREATMENT OF	VASCULAR DISEASE							
APPLICANT(S) FOR DO/EO/US: Ryozo N	AGAI, Takayuki SHINDO, Ichiro MANA	BE, Koichi SHUDO, and Hiroyuki KAGECHIKA							
Applicant herewith submits to the United Stat	es Designated/Elected Office (DO/EO/US)	the following items and other information.							
1. A This is a FIRST submission of items	concerning a filing under 35 U.S.C. 371.								
2. This is a SECOND or SUBSEQUEN	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.								
	This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (23) indicated below.								
4. The US has been elected (PCT Article)	The US has been elected (PCT Article 31).								
 b. has been communicated by the 	nly if not communicated by the International								
 a. is attached hereto. 									
a. are attached hereto (required of the last of the last	, the time limit for making such amendmen	nal Bureau).							
8. An English language translation of the	e amendments to the claims under PCT Ar	ticle 19 (35 U.S.C. 371(c)(3)).							
9. An oath or declaration of the inventor	An oath or declaration of the inventor(s) (35 U.S.C371(c)(4)). "Unexecuted"								
10. An English language translation of the 371(c)(5)).	e annexes to the International Preliminary	Examination Report under PCT Article 36 (35 U.S.C.							
ltems 11 to 16 below concern other docume	nt(s) or information included:								
II. Assignee: RESEARCH FOUNDATION	Assignee: RESEARCH FOUNDATION ITSUU LABORATORY, of Tokyo, Japan								
_	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.								
13. An assignment document for recording	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
14.	minary amendment.								
15. An Application Data Sheet under 37	C.F.R. 1.76.								
16. A substitute specification.									
17. A power of attorney and/or change of	faddress letter.								
18. Figure of Drawing to be published: _									
	uence listing in accordance with PCT Rule								
	national application under 35 U.S.C. 154 (
21. A second copy of the English language	ge translation of the international of the int	ternational application under 35 U.S.C. 154 (d) (4).							
РСТ/IB/301. РСТ/IB/304. РСТ/IB/308.	d in Japanese. apanese. Calculation Sheet (in Japanese).								
PCT/IB/332. Claim of Priority.									



U.S. APPLICATION NO. (I	PLICATION NO. (If known, see 37 CFR 1.5) INTERNATIONAL APPLICATION NO.		ATION NO.	ATTORNEY'S DOCKET NUMBER				
10/	10/511274 PCT/JP03/05084		5084	P26087				
23 The following fees are submitted:					LCULATIONS	PTO USE ONLY		
Basic National F	Fee (37 CFR 1.492(a)(1)-							
Search report has been prepared by the EPO or JPO\$ 950.00								
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33 (1)-(4)								
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)								
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2) paid to USPTO								
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4) \$ 100.00								
ENTER APPROPRIATE BASIC FEE AMOUNT =					950.00			
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).					0.00			
Claims	Number Filed	Number Extra	Rate					
Total Claims	12 - 20 =	0	x \$18.00	\$	0.00			
Independent Claims	5 - 3=	2	x \$88.00	\$	176.00			
Multiple Dependent Clair	m(s) (if applicable)		+ 300.00	\$	0.00	A		
		TOTAL OF ABOVE CA	LCULATIONS =	\$	1,126.00			
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.					0.00			
			SUBTOTAL =	\$	1,126.00			
Processing fee of \$130.00 for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$	0.00			
Extension of Time fee in the amount of \$				\$	0.00			
TOTAL NATIONAL FEE =				\$	1,126.00			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property			\$	0.00				
TOTAL FEES ENCLOSED =				\$	1,126.00			
					Amount to be refunded	\$		
					Charged	\$		
 a. ⊠ A check in the amount of \$1,126.00 to cover the above fees is included. b. ☐ Please charge my Deposit Account No in the amount of \$ to cover the above fees. c. ☒ The U.S. Patent and Trademark Office is hereby authorized to charge any additional fees which may be required, or credit any 								
overpayment to Deposit Account No. <u>19-0089</u> .								
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit car information and authorization on PTO-2038.								
e. Charge any additional fee required under 37 C.F.R. 1.16 and 1.17, including any required extension of time fees in any concurrent or future reply requiring a petition for extension of time for its timely submission (37 CFR 1.136(a)(3)).								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.								
21. Museum								
SEND ALL CORRESPONDENCE TO CUSTOMER NO. 7055 AT THE PRESENT ADDRESS OF: SIGNATURE								
Bruce H. Bernstein				14	eg Nb. 33	,329		
GREENBLUM & BERNSTEIN, P.L.C.					Bruce H. Bernstein			
1950 Roland Clark Place Reston, VA 20191					NAME			
(703) 716-1191					29,027			
1	1 * , 1]	REGISTRATION	NUMBER		

P26087.P02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Ryozo NAGAI et al.

Appl. No:

Not Yet Assigned (U.S. National Phase of PCT/JP03/05084)

Filed

Concurrently Herewith (I.A. Filed April 22, 2003)

For

MEDICAMENT FOR THERAPEUTIC TREATMENT OF VASCULAR

DISEASE

COVER LETTER ACCOMPANYING U.S. NATIONAL STAGE PATENT APPLICATION FILED UNDER 35 U.S.C. 371 AND 37 C.F.R. 1.495

Mail Stop PCT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Enclosed is a new National Stage patent application for filing in the U.S. Patent and Trademark Office under 35 U.S.C. 371 and 37 C.F.R. 1.495. The Declaration and Power of Attorney attached thereto are in unexecuted form. A properly executed Declaration and Power of Attorney of the International Application as filed, will be filed within the period of time set in a Notification to be mailed by the United States Patent and Trademark Office.

Related to the above, this application should be associated with Customer Number 7055, which includes the present correspondence address as follows:

GREENBLUM & BERNSTEIN P.L.C. 1950 Roland Clarke Place Reston, VA 20191 P26087.P02

If there are any questions pertaining to this National Stage Application, please contact the undersigned.

> Respectfully submitted, Ryozo NAGAI et al.

Foslie Mayerne Poglo
Bruce H. Bernstein
Reg. No. 29,027

33,329

October 20, 2004 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191